| Name | Title | Contact Details |
|---|
Illinois State Medical Society is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Brighton Health Group is BHPS`s parent company whose approach it is to create an ecosystem in which everyone`s success is contingent upon better health for patients. BHG`s businesses collaborate with physicians, payors and plan sponsors to align the economics with better results, enabling consumers to make better decisions. Combining expertise in healthcare economics with operations drives transformation across the healthcare value chain. BHG aligns financial incentives with quality outcomes and clinical accountability. This formula is building a sustainable business model based on shared rewards between the providers, payors, and health plan sponsors.
"Eleven uses its proprietary technology platform to create first-of-a-kind protein therapeutics to address unmet needs for ophthalmic diseases. Proteins are able to modulate inflammatory cytokines, key targets in ocular disease that have been difficult to access with conventional therapeutic approaches. A significant untapped opportunity exists for protein therapeutics to address ophthalmic diseases, and Eleven is applying its advanced protein technology and expertise to develop innovative medicines for patients suffering from ocular diseases. Eleven`s team of industry veterans has deep experience in understanding protein science and biologic drug development, designing and conducting clinical trials and, most importantly, applying specific expertise in ophthalmic disease to create novel ocular therapeutics to treat unmet medical needs. Eleven has developed a proprietary pipeline of ophthalmic drug candidates derived from the company`s innovative AMP-Rx protein engineering technology. The company`s initial product candidates are focused on targeting inflammatory cytokines and key targets of ocular disease by blocking the cytokines and modulating the biological processes that drive ocular disease. Current pipeline opportunities include ocular surface diseases such as dry eye disease (DED) and allergic conjunctivitis (AC), and back of the eye diseases such as diabetic macular edema (DME) and uveitis. In addition, Eleven’s proprietary technology has been utilized to prolong the intravitreal half-life of our pipeline products. Beyond its internal drug development programs, Eleven works with collaborators, such as ThromboGenics, to apply its innovative protein therapeutic design capabilities to engineer and develop biotherapeutic products for additional therapeutic targets. EBI-005, Eleven`s lead product candidate, is a novel interleukin-1 (IL-1) receptor antagonist in Phase 3 clinical development as one of the first topically administered proteins for the treatment of DED and AC, two inflammatory diseases at the surface of the eye."
We aim to advance urologic patient care through bold innovation, based on diversity of thought, openness to new ideas, adaptation to change, integrity and compassion. We develop innovative therapies and participate in exceptional licensing opportunities. Our goal is to be the leading specialty company: recognized and trusted by patients and providers for our commitment to urology. Urologic conditions can have a major impact on daily life, with those affected often suffering in silence as their conditions are overlooked, misunderstood or not adequately treated.
EnWave Corporation is a Prince George, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.